A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive; HER2-Positive; Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel; Carboplatin; Trastuzumab; and Pertuzumab (TCHP) With or Without Estrogen Deprivation